Happy to announce Claris Bio is officially emerging from stealth! https://lnkd.in/ed__vXdW
Claris Bio
Biotechnology Research
Jersey City, New Jersey 433 followers
Leading the way in corneal therapy
About us
Claris Bio, based in Jersey City, NJ, was founded by a group of experienced biopharma industry executives and experts in ophthalmology. The company’s foundational intellectual property is based on work done at the Massachusetts Eye and Ear Infirmary by Dr. Reza Dana, MD, MSc, MPH, Claes Dohlman Chair in Ophthalmology, Harvard Medical School and Senior Scientist and Director of Cornea at Mass Eye and Ear and Dr. Sunil Chauhan, DVM, PhD, Principal Investigator and Associate Professor, Mass Eye and Ear, Harvard Medical School. Claris’ lead program, CSB-001 Ophthalmic Solution 0.1%, brings a topical ocular biologic solution of oremepermin-α, a molecule with the potential to restore structural and functional corneal integrity, to eyes with neurotrophic keratopathy (NK). For more information about Claris, please visit www.clarisbio.com.
- Website
-
https://clarisbio.com/
External link for Claris Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Jersey City, New Jersey
- Type
- Privately Held
Locations
-
Primary
Get directions
Jersey City, New Jersey, US
Employees at Claris Bio
Updates
-
Today, Claris Bio emerges from stealth to focus on corneal disease therapies. With $57 million in funding and a late-stage lead program study, CSB-001 Ophthalmic Solution 0.1% (oremepermin-α), which is expected to readout later this year, we are focused on creating a pipeline using oremepermin-α across multiple ophthalmic diseases. With a management team led by Claris Bio Founding CEO Clarke Atwell, CMO Susan Orr, OD, and CBO Henry Rath, as well as our investors, Novo Holdings A/S, RA Capital, Mass General Brigham Ventures and Janus Henderson Investors, we are well-positioned to develop the next new standard of care for numerous corneal diseases. To learn more about Claris Bio, please visit www.clarisbio.com.Today, Claris Bio emerges from stealth to focus on corneal disease therapies. With $57 million in funding and a late-stage lead program study, CSB-001 Ophthalmic Solution 0.1% (oremepermin-α), which is expected to readout later this year, we are focused on creating a pipeline using oremepermin-α across multiple ophthalmic diseases. With a management team led by Claris Bio Founding CEO Clarke Atwell, CMO Susan Orr, OD, and CBO Henry Rath, as well as our investors, Novo Holdings A/S, RA Capital, Mass General Brigham Ventures and Janus Henderson Investors, we are well-positioned to develop the next new standard of care for numerous corneal diseases. To learn more about Claris Bio, please visit www.clarisbio.com.
Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24
globenewswire.com